US20220401358A1 - Powder formulations for inhalation - Google Patents

Powder formulations for inhalation Download PDF

Info

Publication number
US20220401358A1
US20220401358A1 US17/783,536 US202017783536A US2022401358A1 US 20220401358 A1 US20220401358 A1 US 20220401358A1 US 202017783536 A US202017783536 A US 202017783536A US 2022401358 A1 US2022401358 A1 US 2022401358A1
Authority
US
United States
Prior art keywords
pharmaceutical formulation
mixing element
powdered pharmaceutical
cavity
walls
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/783,536
Other languages
English (en)
Inventor
Regina SCHERLIESS
Simon Stefan Bock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Christian Albrechts Universitaet Kiel
Original Assignee
Christian Albrechts Universitaet Kiel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christian Albrechts Universitaet Kiel filed Critical Christian Albrechts Universitaet Kiel
Assigned to CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL reassignment CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Bock, Simon Stefan, SCHERLIESS, Regina
Publication of US20220401358A1 publication Critical patent/US20220401358A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
    • A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
    • A61M15/005—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a cylindrical surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Definitions

  • the present invention relates to powdered pharmaceutical formulations containing a particulate active ingredient and carrier particles to which the active ingredient adheres preferably only superficially, and to a process for producing such formulations.
  • the formulations are characterized in that they contain a mixing element which is freely movable in the formulation and forms a dispersing aid for the particulate active ingredient and the carrier particles.
  • the mixing element may be arranged in a section of the flow channel of an inhaler, e.g. freely movable in a chamber through which carrier gas and powdered pharmaceutical formulation flow.
  • the invention also relates to the mixing element and to a method of producing it, and further to preferred carrier particles and methods of producing them.
  • the mixing element has the advantage of producing a larger proportion of fine particles in the carrier gas from a powdered formulation, the fine particles having a size suitable for penetration into the lungs of, for example, 5 ⁇ m or less, when the formulation is swirled by means of a carrier gas, e.g. when a particle cloud is generated during inhalation.
  • Hickey, A., KONA Powder and Particle Journal 35 (2016) 3-13 for inhalation describes powdered pharmaceutical formulations for inhalation comprising as carrier particles lactose crystals, e.g. ground and sieved, and adhering thereto separately spray-dried or micronized active ingredient.
  • the invention has the object of providing an alternative powdered pharmaceutical formulation and a process for its production.
  • the formulation is intended to produce as high a proportion as possible of particulate active ingredient of an aerodynamic particle size of at most 5 ⁇ m during distribution, in order to make the active ingredient particles inhalable or respirable.
  • a further object lies in the provision of a mixing element suitable for fluidizing particulate active ingredient of a particle size of maximum 5 ⁇ m, in particular from a powdered pharmaceutical formulation in the carrier gas stream, and in the provision of a production process for such mixing elements.
  • the invention achieves the object by the features of the claims and, in particular, by a powdered pharmaceutical formulation which, in addition to carrier particles and particulate active ingredient, which preferably adheres to the surface of the carrier particles, optionally contains a mixing element, wherein the formulation fluidized in the carrier gas stream can contain the mixing element.
  • the carrier particles preferably have one and the same shape and size, so that the carrier particles are uniform in shape and size.
  • the powdered pharmaceutical formulation is packaged as a single dose, e.g., filled as a single dose in a container, e.g., in a capsule.
  • the formulation consisting of particulate active ingredient and of carrier particles may be contained in a reservoir in the inhaler from which a single dose is divided prior to dispersion or fluidization.
  • the mixing element has a size in a first dimension of at least 1 mm, preferably of at least 1.5 mm or of at least 2 mm, e.g. up to 10 mm or up to 9 mm or up to 8 mm or up to 7 mm, and in the other two dimensions a size of at least 50%, preferably at least 60%, at least 70%, at least 75%, at least 80% or at least 90% of the size it has in the first dimension.
  • the formulation has the active ingredient in particle sizes of the individual particles of 5 ⁇ m or less, wherein particles in the formulation may be agglomerated, e.g. adhering to the surface of carrier particles.
  • the mixing element contained in the powdered pharmaceutical formulation has walls disposed about a cavity and having at least one aperture open to the cavity.
  • the walls encompass the at least one aperture and open up a cavity between them, such that the cavity is open through the at least one aperture.
  • the mixing element has walls disposed around the cavity the walls having at least two apertures disposed on opposing walls and open to the cavity.
  • the walls of the mixing element have, between their outer surface and the cavity, a thickness of, for example, at most 20% or of at most 15% or of at most 10% of the size of the mixing element in this dimension.
  • the walls may have on their surfaces a total area of at most 50%, at most 40%, at most 30% or at most 20% or at most 10% of the total area of the at least one aperture opened up by the walls.
  • the walls may together take up a total area, determined with respect to the cavity, which is at most 50% of the area spanned by the at least one aperture, so that the walls cover a smaller proportion of the cavity than the at least one recess spans across the cavity.
  • the mixing element may have walls that allow rolling, in particular continuous rolling, along inner surfaces of a container, which may be a dispersion chamber or fluidization chamber, e.g. in the flow path or flow channel of an inhaler, or a storage container.
  • the walls of the mixing element may be convexly curved, for example, on their surfaces opposite the cavity.
  • the surfaces of the walls opposite the cavity, which form the outer surfaces of the walls and respectively of the mixing element can be formed continuously or in sections.
  • the continuously formed convexly curved surfaces may extend, for example, over at least 1 ⁇ 4, 1 ⁇ 3 or 1 ⁇ 2 of the circumference.
  • This embodiment of the mixing element has been shown to cause higher fluidization of particles smaller than 5 ⁇ m when the powdered composition is swirled with a carrier gas, for example, compared to fluidization of an otherwise identical formulation without a mixing element.
  • the higher fluidization of small particles is currently attributed to the dispersing effect of the mixing element on the formulation.
  • the mixing element may have walls formed by one or by at least two interconnected wall sections, each closed in on itself around an aperture, which extend in at least two planes lying, for example, at an angle of 45° to 90° to one another.
  • the mixing element may be solid with a self-contained surface of, for example, of a sphere, of a pyramid, of a cylinder, of a three-dimensional oval, of a cuboid, of a cube, of a cone, of a truncated cone, or of a polyhedron.
  • a solid mixing element has protrusions.
  • protrusions may terminate in a curved plane that allows the mixing element to roll along interior surfaces of a storage container.
  • the ends of the projections may form portions of a curved plane, respectively may form support points on which the mixing element rolls along the inner surface of a storage container.
  • a mixing element increases the proportion of fine particles of a maximum size of 5 ⁇ m that pass from the pharmaceutical formulation into the carrier gas by means of a carrier gas.
  • the mixing element leads to an increase in the content of fine particles of a maximum size of 5 ⁇ m during fluidization of the pharmaceutical formulation in the carrier gas and therefore to increased entry of such particles into the lungs during inhalation.
  • the mixing element leads to the fluidization of fine particles, e.g. of a size of at maximum 4 ⁇ m, of at maximum 3 ⁇ m or of at maximum 2 ⁇ m, which can be inhaled into the peripheral regions of a lung.
  • the mixing element is produced from a hardening mass by means of an additive manufacturing process, which is also generally known as a 3D printing process.
  • mixing elements can be produced from a precursor mass by controlled radiation-induced curing, e.g. melt solidification or polymerization, which is also generally known as photopolymerization or laser lithography, respectively.
  • Mixing elements can, for example, be made of pharmaceutically acceptable plastic that is biologically resistant or that is biodegradable.
  • Biodegradable plastic is e.g. polylactide, polyglycolide, polylactide-co-glycolide (PLGA).
  • a biologically resistant plastic is e.g. EVA or PMMA.
  • the carrier particles of the formulation have a uniform size of at maximum 500 ⁇ m e.g. 50 to 500 ⁇ m or up to 400 ⁇ m or up to 350 ⁇ m in the longest extension, and a uniform shape.
  • a uniform shape is generally an identical three-dimensional shape in each case. It has been shown that a uniform size and shape of the carrier particles enhances fluidization of the carrier particles and of the active ingredient that can adhere to the carrier particles by a gas stream and/or enhances the release of particulate active ingredient from the carrier particles within the respiratory tract.
  • the carrier particles are preferably also produced by means of an additive manufacturing process, e.g. by a 3D printing process or by photopolymerization.
  • the carrier particles preferably consist of material that can be degraded by a human body, e.g., after introduction of carrier particles into the upper respiratory tract or lungs.
  • material of which carrier particles may consist include polylactide, polyglycolide, polylactide-co-glycolide (PLGA), sugars, in particular glucose and lactose, sugar alcohols, in particular mannitol, cellulose, cellulose derivatives, e.g. hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, gelatine, alginate, agarose, carrageen, and mixtures of at least two of these.
  • PLGA polylactide, polyglycolide, polylactide-co-glycolide
  • sugars in particular glucose and lactose
  • sugar alcohols in particular mannitol
  • cellulose cellulose derivatives, e.g. hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl
  • the carrier particles preferably have uniformly the same shape and the same size.
  • the shape may be one as described with reference to the mixing element, but with the size of a maximum 500 ⁇ m, e.g. 50 to 300 ⁇ m, in each dimension.
  • the carrier particles having the same size and shape, respectively having the identical shape are produced by an additive manufacturing process, in particular by means of a photolithographic process or by means of a 3D printing process.
  • the invention also provides an inhaler having a mixing element contained in the flow path thereof, e.g., in a dispersion chamber therein.
  • a formulation of carrier particles and active ingredient is brought into contact with the mixing element in the section of the flow path in which the mixing element is contained.
  • This section of the flow path may be, for example, its dispersion chamber.
  • the mixing element is generally free to move in the section of the flow path and is retained, for example, by an outlet opening having a cross-section smaller than the mixing element.
  • the active ingredient can be a combination of at least two active ingredients.
  • the aerodynamic size of particles is determined using Apparatus E according to European Pharmacopeia 9.0.
  • FIG. 1 shows exemplary shapes for mixing elements and for carrier particles.
  • FIG. 1 shows shapes of the mixing element and of carrier particles. Shapes which are solid, respectively have no cavity, are e.g. the pyramids 1 to 4 , the spherical polyhedra 5 to 20 as well as 43 to 45 and 74 as well as 76 , 58 as well as 79 or 81 , the cylinder 21 as well as cylinders 46 and 47 and 53 to 54 with chamfered end faces, the cubes 22 , 27 and 31 to 33 , the L-shaped angle 23 , the U-shaped angle 24 , the edge lengths of which are preferably equal, the plates 25 and 26 , the cylinders with tapered end faces 37 to 40 and 59 to 63 , the cuboids 41 and 42 with pentagonal or polygonal cross-section and flat, parallel end faces, cones and truncated cones 48 to 52 , solid hemisphere 55 , solid quarter sphere 56 , solid 2 ⁇ 3-sphere 57 , a spherical shape with protrusions 69 or 70
  • Shapes whose walls encompass a cavity are e.g. hollow cylinders 29 and 30 , rings 34 to 36 and 88 , optionally with serrated protrusions, lattice spheres 64 to 67 , which consist of walls arranged in the shape of spherical shells opening up apertures between them, and preferably shapes 28 , 68 , 78 , 83 , 89 and 90 , which consist of at least one intertwined strip extending in at least two planes arranged at an angle of 60 to 90° to each other and whose outwardly facing surfaces are convexly curved and form an at least sectionally, preferably a continuous spherical rolling surface, wherein the at least one strip encompasses a cavity and opens up apertures between sections of the strip.
  • the intertwined strip may have a circular or angular cross-section.
  • the shape 90 is also known as a rolling knot.
  • the mixing element was made of filamentous polylactide or polyvinyl alcohol (both from Ultimaker B.V, Utrecht, The Netherlands) by melting and metering the melt according to a predetermined pattern by 3D printing or by a photolithographic process from a light polymerizable precursor mass of the polymers in the forms shown as No. 88, No. 89 and No. 90, respectively, in FIG. 1 .
  • the size of the mixing elements along their respective maximum extension was 7 mm.
  • the mixing element of shape No. 90 has cavities between arcuate walls that are open at a plurality of apertures bordered by the walls.
  • the mixing elements of shape No. 88 and No. 90 have walls whose surfaces opposite the cavity are convexly curved and promote rolling along an inner surface of, for example, a mixing chamber.
  • the mixing element of shape No. 89 has cavities enclosed by the walls and walls whose surfaces opposite the cavities are convexly curved and promote rolling along an inner surface of, for example, a mixing chamber. Therein, the convexly curved surfaces of the mixing elements of forms No. 90 and No. 89 are continuous.
  • the lactose (InhLac 120) and the active ingredient were passed through a 355 ⁇ m mesh sieve at 20-25° C., 30-65% relative humidity and then mixed at a speed of 500 rpm (Picomix, Hosokawa Alpine, Augsburg, Germany), twice for 60 s each with one sieving (355 ⁇ m mesh) in between.
  • This mixture of the active ingredient and the lactose was fluidized according to one embodiment, wherein the mixing element was placed in the dispersion chamber and thus in the flow path of the inhaler.
  • capsules Vcaps Plus, size 3, Lonza, Basel
  • the capsules were individually placed in a powder inhaler, available under the name “Twister” from Aptar, Louveciennes, France, for measurement of the fine fraction of active ingredient produced after fluidization.
  • the powder inhaler was attached to an impactor through which an air stream generated by a vacuum pump was drawn, the flow rate of which was adjusted by a digital flow meter (model DFM3, Copley Scientific, Nottingham, England) to the flow rate corresponding to a pressure drop of 4 kPa across the inhaler, as determined at the dose collection tube according to Ph. Eur 9.0.
  • a controlled valve was set to an opening time that at the flow rate resulted in an air volume of 4 L, according to Ph. Eur.
  • the aerodynamic size distribution of particles was determined using a Next-Generation Pharmaceutical Impactor (Apparatus E according to European Pharmacopeia 9.0). Following the analysis, the deposited drug in each section of Apparatus E was dissolved with water after analysis and analyzed separately for drug content by HPLC (RP18 column, detection at 220 nm, mobile phase: 22% acetonitrile, 78% buffer of 2.87 g/L sodium heptasulfonate, 2.50 g/L potassium hydrogen phosphate, pH 3.65, adjusted with 85% orthophosphoric acid, 25° C., flow rate 0.89 mL/min, 10 ⁇ L sample volume). Using the Copley Inhaler Testing Data Analysis Software 3.0 (Copley Scientific Ltd.), fine particle mass and fine particle fraction (based on delivered dose) were calculated from aerodynamic particle size distribution (corresponding to PhEur).
  • the table shows the measured masses and changes in % in relation to the formulation without mixing element.
  • the small cube has an edge length of 3.8 mm
  • the medium cube has an edge length of 4.8 mm
  • the large cube has an edge length of 5.8 mm.
  • one mixing element per capsule was added to the powdered pharmaceutical formulation of lactose and active ingredient, and this capsule was introduced into the dispersion chamber of the inhaler, where it was subsequently fluidized in the gas stream.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
US17/783,536 2019-12-10 2020-12-02 Powder formulations for inhalation Pending US20220401358A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102019219277.7 2019-12-10
DE102019219277.7A DE102019219277A1 (de) 2019-12-10 2019-12-10 Pulverförmige Formulierungen zur Inhalation
PCT/EP2020/084271 WO2021115877A1 (de) 2019-12-10 2020-12-02 Pulverförmige formulierungen zur inhalation

Publications (1)

Publication Number Publication Date
US20220401358A1 true US20220401358A1 (en) 2022-12-22

Family

ID=73748032

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/783,536 Pending US20220401358A1 (en) 2019-12-10 2020-12-02 Powder formulations for inhalation

Country Status (4)

Country Link
US (1) US20220401358A1 (de)
EP (1) EP4072635A1 (de)
DE (1) DE102019219277A1 (de)
WO (1) WO2021115877A1 (de)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3653380A (en) * 1970-02-16 1972-04-04 American Cyanamid Co Aerosol powder dosage dispensing device
SE9302550D0 (sv) * 1993-07-30 1993-07-30 Ernst Hoerlin Powder inhaler
US6427688B1 (en) * 2000-02-01 2002-08-06 Dura Pharmaceuticals, Icn. Dry powder inhaler
GB0520794D0 (en) * 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
WO2011152804A2 (en) * 2010-06-03 2011-12-08 Mahmut Bilgic Process for dry powder formulations
CN103917223B (zh) * 2011-09-14 2017-08-08 盐野义制药株式会社 供吸入的药用组合物

Also Published As

Publication number Publication date
EP4072635A1 (de) 2022-10-19
WO2021115877A1 (de) 2021-06-17
DE102019219277A1 (de) 2021-06-10

Similar Documents

Publication Publication Date Title
US9566239B2 (en) Pharmaceutical formulations for dry powder inhalers
EP2916821B1 (de) Hochdosierte levodopakapseln zur pulmonalen verwendung
US8182791B2 (en) Formulations for use in inhaler devices
CA2115065C (en) Ultrafine particle powder for inhalation and method for production thereof
RU2497507C2 (ru) Ингаляционные фармацевтические композиции в форме сухих порошков, растворов или суспензий, полученных из них, и способ их получения
KR20140103939A (ko) 흡입 프로파일-비의존적 약물 전달을 위한 에어로졸화 장치
JPH10502390A (ja) 医薬品用の徐放性マトリックス
PL195574B1 (pl) Cząstki do podawania substancji czynnej do pęcherzyków płucnych, sposób wytwarzania tych cząstek i zastosowanie inhibitora wzrostu higroskopowego
CN106102748A (zh) 用于吸入的干粉制剂
CA2732585A1 (en) Formulations containing large-size carrier particles for dry powder inhalation aerosols
KR20070034598A (ko) 표면상에 파우더 유지력을 최소화하는 방법
US20170172925A1 (en) Process for preparing a medicament
US20220401358A1 (en) Powder formulations for inhalation
KR102462058B1 (ko) 제제의 안정성을 증가시키기 위해 분무 건조에 의해 수득된 1종 이상의 건조 분말을 포함하는 조성물
AU2022202278A1 (en) High Dose Delivery of Inhaled Therapeutics
KR20200105857A (ko) 폐 투여에 의한 우울증의 치료에 사용하기 위한 건조 분말 케타민 조성물
AU2017341350B2 (en) Formulations of cysteamine and cysteamine derivatives
ES2876014T3 (es) Preparación sólida oral con liberación modificada
Young et al. The Orbital® a novel high payload multi-breath dry powder inhaler
ZA200208066B (en) Formulations for use in inhaler devices.

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHERLIESS, REGINA;BOCK, SIMON STEFAN;REEL/FRAME:060195/0185

Effective date: 20220610

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION